SB 1178 appropriates $100,000 from Oklahoma's General Revenue Fund to the Department of Human Services for fiscal year 2026 to support its existing mental health and substance abuse services duties. The bill directly affects state-funded mental health programs by providing dedicated funding for current operations. It includes an emergency clause, allowing it to take immediate effect without the governor's signature, which occurred on May 29, 2025. This is a procedural funding measure with no new policy requirements, solely allocating existing resources. The appropriation is limited to the specified amount and purpose as defined in the bill text.
HB 2788 transfers specific funds back into Oklahoma's Statewide Recovery Fund from several existing programs. It moves $1.56 million from domestic violence services, $162,668 from food assistance programs, $1.49 million from health workforce initiatives, $2.16 million from rural healthcare, $5 million from medical facilities, $20.5 million from mental health hospital construction, and $3.3 million from water resources projects. All transfers align with recommendations from the Joint Committee on Pandemic Relief Funding. The bill takes effect July 1, 2025, and was enacted without the governor's signature on May 29, 2025.
SB 109 requires Oklahoma health insurance plans to cover genetic testing for inherited cancer risks and evidence-based cancer imaging for individuals with a personal or family history of cancer or increased cancer risk. This coverage must be provided without patient cost-sharing (such as deductibles or copays) when ordered by a healthcare provider following current medical guidelines, including those from the National Comprehensive Cancer Network. The law applies to all health benefit plans offered in Oklahoma starting November 1, 2025, ensuring these preventive services are accessible without financial barriers. It does not affect health savings account eligibility for non-preventive services but guarantees coverage for preventive care under federal guidelines.
SB 1136 allocates $100,000 from Oklahoma's General Revenue Fund to the Oklahoma Health Care Authority (OHCA) for unspecified duties required by law. The bill directly affects the OHCA, which administers state health care programs, by providing dedicated funding for its operations. It requires the agency to use these specific funds for purposes outlined in existing law, though the bill does not detail the exact programs or services. The funding is effective immediately upon the bill's passage, declared an emergency for public health and safety reasons. This is a routine appropriations measure with no new policy requirements or beneficiary changes.
SB 176 requires health insurance plans to cover certain prescription drugs that were previously not included in standard coverage. It directly affects health insurance providers and policyholders by mandating this specific coverage for eligible medications. The key provision is a new requirement for all health benefit plans to include these designated prescriptions without prior authorization or excessive cost-sharing. The law became effective on May 29, 2025, after the Governor did not sign it.
SB 1141 allocates $100,000 from unallocated state general revenue funds to Oklahoma's Department of Mental Health and Substance Abuse Services for its existing statutory duties. The bill requires these specific funds to be used for mental health services without creating new programs or altering current service requirements. An emergency clause makes the law effective immediately upon passage, bypassing the typical governor's signature requirement. The bill became law on May 29, 2025, after being passed without gubernatorial action.
SB 1140 allocates $100,000 from unspent state general revenue funds to Oklahoma's Department of Mental Health and Substance Abuse Services for purposes already required by law. The bill directs the department to use these funds for its existing duties, without creating new programs or services. It includes an emergency provision allowing immediate implementation upon enactment, bypassing the usual waiting period. The bill became law on May 29, 2025, without the governor's signature. This is a procedural funding measure, not a substantive policy change.
HB 2013, "Dylan's Law," requires health insurance companies to cover epilepsy treatments equally to other conditions, prohibits dropping coverage solely due to an epilepsy diagnosis, and mandates coverage for medically necessary neurostimulation devices. It also allows individuals with epilepsy (diagnosed by a licensed doctor) to voluntarily add a unique symbol to their Oklahoma driver's license or ID card by June 1, 2026, to help first responders identify their condition during emergencies. The symbol cannot be used for any other purpose and may be removed at any time. These provisions became law on May 25, 2025, without a gubernatorial signature. The bill directly affects people with epilepsy and insurers operating under the Affordable Care Act in Oklahoma.
HB 2052 exempts certain domestic health maintenance organizations (HMOs) that exclusively contract with Oklahoma's Medicaid program (via the Oklahoma Health Care Authority) from most state health insurance regulations. These HMOs, which serve only Medicaid recipients and no other patients, are no longer subject to specific provisions of the Health Maintenance Organizations Act, including requirements about benefit coverage and certain administrative rules. The exemption applies solely to services provided to Medicaid recipients under Oklahoma Statutes Title 56, Section 4002.2. The law became effective November 1, 2025, after passing without the Governor's signature.
SB 927 amends Oklahoma's Medicaid Drug Utilization Review Board procedures by prohibiting the pharmaceutical industry representative from voting on drug-related matters. It updates the appointment process to stagger initial terms for one physician, one pharmacist, and the lay representative to ensure board continuity. The bill affects the Oklahoma Health Care Authority and the board members, with changes taking effect November 1, 2025. The board's composition (10 members: 4 physicians, 4 pharmacists, 1 lay representative, 1 pharmaceutical industry rep) and appointment lists remain unchanged.
